Purpose: Type II collagen, encoded by COL2A1 gene, is a phenotypic marker of articular cartilage whose expression is strongly decreased during osteoarthritis (OA) process. Specific proteins (Sp) and Sox proteins have been previously characterized to be major regulators of this gene. Besides, the existence of a link between estrogen deprivation and osteoarthritis in postmenopausal women suggests that 17β-estradiol (17β-E 2 ) may be a critical modulator of cartilaginous matrix homeostasis. The aim of present study was to investigate the molecular mechanisms regulating type II collagen gene expression under the effect of 17β-E 2 , and to characterize the genomic pathway via estrogen receptors (ER). Methods: Articular chondrocytes were isolated from 3-week old rabbits and incubated for 24 hours with increasing concentrations of 17β-E 2 (0 to 10 nM). Nuclear proteins were extracted and submitted to gel retardation assays in order to determine Sp and Sox proteins binding activities on COL2A1 gene. In some experiments, relative expression of Sp1/Sp3 or Sox-9 was inhibited by siRNAs strategies. Moreover, chromatin immunoprecipitation was used to study protein-protein interactions on COL2A1 promoter and enhancer sequences.
Purpose:
The study was designed to find synergistic effects of salmon calcitonin (sCT) with reference treatments for (osteo)arthrits in the bovine cartilage explant model in which degradation is induced by a cocktail of three cytokines. Methods: Matrix degradation was quantified by measuring proteoglycan release, collagen release and MMP activity. The pro-inflammatory molecule PGE2 was also measured. In the first experiment maximum ineffective concentrations of sCT, Galardin, Celebrex, Dexamethasone, BB-94 and Doxycyclin were determined. In the second experiment, combinations of sCT with each of the other drugs were assayed to determine if there was a statistically significant synergistic effect of the combination Results: Calcitonin (0.5 nM) and Doxycyclin (10 μM) alone had a no effect on collagen release. They change the collagen release from 135 to 133 and 125 ng CTX-II per mg cartilage respectively. The combination, however, decreased the collagen release to 73 ng CTX-II per mg cartilage. This effect is stronger then expected based on the effects of the compounds alone and is therefore synergistic. A similar effect is observed for the combination of Calcitonin (0.5 nM) with BB-94 (10 nM). Alone they change the collagen release from 135 to 133 and 137 ng CTX-II per mg cartilage respectively, while the combination reduced the collagen release to 88 ng CTX-II per mg cartilage. Although no synergy of sCT with the other compounds was detected in this study, further experiments to determine a more appropriate range of concentrations of each of the compounds needs to be carried out.
Conclusions:
The combination of sCT with with doxycyclin and BB-94 can act synergistically to reduce type II collagen degradation in a bovine cartilage explant model. These results lend support to the concept that a combination therapy to reduce matrix degradation in OA can be developed with very low doses of each of the compounds. Such a combination therapy has the potential to alleviate the safety concerns with high doses of doxycyclin or BB-94. Purpose: The role of aspartyl proteases in osteoarthritis has been relatively unexplored. BACE-1 is an aspartic-acid protease important in the pathogenesis of Alzheimer's disease and in the formation of myelin sheaths in peripheral nerve cells. BACE-1 is currently a target for therapeutic intervention in neural degenerative diseases and the goal of these studies was to explore its role in cartilage metabolism. Methods: Selective small molecule inhibitors of BACE-1 were tested for their ability to block cartilage breakdown in various pre-clinical assays. Results: In these studies selective inhibition of BACE with various small molecules blocked the cytokine induced glycosaminoglycan release in both bovine and human cartilage explant cultures. Furthermore, immunostaining of human OA cartilage sections showed that BACE-1 protein was localized in areas of cartilage undergoing matrix breakdown and fibrillation. Gene expression profiling suggested that the effect of BACE inhibition is partly through the regulation of MMP13 message. Finally, BACE-1 null mice are currently being analyzed for resistance to cartilage erosion in a surgical instability model of OA. Conclusions: These findings identify a novel role for BACE-1 in cartilage breakdown, raising the possibility that BACE-1 inhibitors will act as therapeutics not only in Alzheimer's, but in arthritic diseases as well. Purpose: Hypertrophic chondrocytes release proteinases resulting in a loss of extracellular matrix compounds in osteoarthritis (OA. In the search for molecular mechanisms leading to chondrocyte hypertrophy epigenetic events have been discussed. In a genome-wide methylation analysis we identified a consistent hypomethylation of the gene coding for the integrine LAMA4 in OA chondrocytes Methods: We obtained 15 samples of human osteoarthritis cartilage during total knee joint replacement. Immunohistochemistry for LAMA4 was performed after histological grading for OA according to the OARSI score. Isolated chondrocytes were cultured in the presence of 5-AZAdeoxy-cytidine and expression of LAMA4 was quantified using the Taqman Realtime PCR Assay.
267

268
LAMA4 IS EXPRESSED BY CLUSTERS OF HYPERTROPHIC CHONDROCYTES IN OSTEOARTHRITIC CARTILAGE AND REGULATED BY EPIGENETIC MECHANIMS
